Ken Griffin Oncocyte Corp Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.2 - $0.35 $50,390 - $88,183	251,952 New	251,952 $57,000
Q3 2022 Nov 14, 2022	SELL	$0.76 - $0.99 $170,287 - $221,822	-224,063 Reduced 89.08%	27,454 $20,000
Q2 2022 Aug 15, 2022	BUY	$0.86 - $1.53 $181,165 - $322,305	210,657 Added 515.56%	251,517 $226,000
Q1 2022 May 16, 2022	BUY	$1.15 - $2.25 $9,650 - $18,882	8,392 Added 25.85%	40,860 $61,000
Q4 2021 Feb 14, 2022	SELL	$2.04 - $3.59 $4,561 - $8,027	-2,236 Reduced 6.44%	32,468 $70,000

Q3 2021 Nov 15, 2021	SELL	$3.53 - $5.89 $116,634 - $194,611	-33,041 Reduced 48.77%	34,704 $124,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $6.0 $182,754 - $290,856	-48,476 Reduced 41.71%	67,745 $388,000
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $145,496 - $395,700	60,877 Added 110.0%	116,221 $603,000
Q4 2020 Feb 16, 2021	BUY	$1.38 - $2.63 $52,325 - $99,721	37,917 Added 217.58%	55,344 $132,000
Q3 2020 Nov 16, 2020	SELL	$1.2 - $1.89 $21,840 - $34,398	-18,200 Reduced 51.08%	17,427 $24,000
Q2 2020 Aug 14, 2020	BUY	$1.91 - $3.45 $24,774 - $44,749	12,971 Added 57.25%	35,627 $68,000
Q1 2020 May 15, 2020	BUY	$1.76 - $3.02 $13,219 - $22,683	7,511 Added 49.59%	22,656 $56,000
Q2 2019 Aug 14, 2019	SELL	$2.49 - $5.45 $6,538 - $14,311	-2,626 Reduced 14.78%	15,145 $38,000
Q1 2018 May 11, 2018	BUY	$1.25 - $4.6 $22,213 - $81,746	17,771 New	17,771 $37,000

1.16M

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $350M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.